Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Billaud

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 14, 2009
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agentsRoger J M Brüggemann, Jan-Willem C Alffenaar, Nicole M A Blijlevens, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 24, 2009
Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patientsM Berge, R Guillemain, V Boussaud, et al.
Oncogene|January 23, 1997
Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutationsM Rossel, A Pasini, S Chappuis, et al.
European Journal of Clinical Pharmacology|November 2, 2010
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patientsMaud Berge, Romain Guillemain, David A Trégouet, et al.
Plos One|March 29, 2013
Expression of calcineurin activity after lung transplantation: a 2-year follow-upSylvia Sanquer, Catherine Amrein, Dominique Grenet, et al.
Oncogene|August 24, 2011
Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1H Gaude, N Aznar, A Delay, et al.
Therapeutic Drug Monitoring|March 17, 2016
Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific CommitteeChristoph Seger, Maria Shipkova, Uwe Christians, et al.
Oncogene|July 8, 2014
A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic propertiesR Dahmani, P-A Just, A Delay, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 25, 2018
Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort studyClaire A Aguilar, Bassem Hamandi, Christine Fegbeutel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposureAntonin Schmitt, Laurence Gladieff, Céline M Laffont, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 14, 2009
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agentsRoger J M Brüggemann, Jan-Willem C Alffenaar, Nicole M A Blijlevens, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 24, 2009
Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patientsM Berge, R Guillemain, V Boussaud, et al.
Oncogene|January 23, 1997
Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutationsM Rossel, A Pasini, S Chappuis, et al.
European Journal of Clinical Pharmacology|November 2, 2010
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patientsMaud Berge, Romain Guillemain, David A Trégouet, et al.
Plos One|March 29, 2013
Expression of calcineurin activity after lung transplantation: a 2-year follow-upSylvia Sanquer, Catherine Amrein, Dominique Grenet, et al.
Oncogene|August 24, 2011
Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1H Gaude, N Aznar, A Delay, et al.
Therapeutic Drug Monitoring|March 17, 2016
Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific CommitteeChristoph Seger, Maria Shipkova, Uwe Christians, et al.
Oncogene|July 8, 2014
A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic propertiesR Dahmani, P-A Just, A Delay, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 25, 2018
Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort studyClaire A Aguilar, Bassem Hamandi, Christine Fegbeutel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposureAntonin Schmitt, Laurence Gladieff, Céline M Laffont, et al.
Pageof 10